SBIR Phase I: Bioluminescence Resonance Energy Transfer Assays for Clinical Chemistry

这项小企业创新研究（SBIR）一期研究项目旨在开发一种肌酸激酶（一种重要的毒性生物标志物）的即时检测方法，以使用全血筛查药物不良反应（adr）。该检测将利用结合量子点的生物发光共振能量转移（BRET）探针。拟议的技术可能会影响毒性测试，使医生能够在早期阶段检测潜在的不良反应并采取纠正措施。超过50%的医疗保险患者服用多种药物，不良反应的可能性很高，任何廉价和可靠的毒性测试都将有利于这些个人和整个社会。

This Small Business Innovation Research (SBIR) Phase I research project aims to develop a point-of-care assay for creatine kinase, an important toxicity biomarker, to screen for adverse drug reactions (ADRs) using whole blood. The assay will utilize bioluminescent resonance energy transfer (BRET) probes incorporating quantum dots. The proposed technology is likely to impact toxicity testing, allowing physicians to test for potential ADR at an early stage and take corrective measures. With over 50% of Medicare patients taking multiple medications, the probability of ADRs is high and any inexpensive and reliable test for toxicity would be of benefit to these individuals and society as a whole.